本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NLS Pharmaceutics Ltd.

0.7620
0.0000
成交量:- -
成交額:- -
市值:396.74萬
市盈率:- -
高:0.7620
開:0.7620
低:0.7620
收:0.7620
52周最高:30.80
52周最低:0.7620
股本:520.66萬
流通股本:341.80萬
量比:- -
換手率:- -
股息:- -
股息率:- -
每股收益(LYR):-2.6288
淨資產收益率:-862.92%
總資產收益率:-75.98%
市淨率:1.41
市盈率(LYR):-0.29

資料載入中...

2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/01/18

SEC問詢函

CORRESP [Cover] - Correspondence
2023/01/03

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/12/16

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/12/13

SEC問詢函

CORRESP [Cover] - Correspondence
2022/06/17

SEC問詢函

CORRESP [Cover] - Correspondence
2022/06/10

招股説明書

F-1 - Registration statement for certain foreign private issuers
2022/03/24

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/24

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/18

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/10

SEC問詢函

CORRESP [Cover] - Correspondence
2022/01/11

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/04

SEC問詢函

CORRESP [Cover] - Correspondence
2021/12/20

招股説明書

F-1 - Registration statement for certain foreign private issuers
2021/11/01

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/11/01

SEC問詢函

CORRESP [Cover] - Correspondence
2021/10/22

招股説明書

F-1 - Registration statement for certain foreign private issuers
2021/10/08

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals